DBV Technologies | DBVT - Current Assets


DBV Technologies reported $88.88M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.08B 115.87M Sep/2025
Alnylam Pharmaceuticals USD 3.95B 309.11M Sep/2025
Amarin USD 628.33M 21.52M Sep/2025
BioMarin Pharmaceutical USD 3.85B 49.21M Sep/2025
DBV Technologies USD 88.88M 32.36M Sep/2025
Halozyme Therapeutics USD 1.33B 206.08M Sep/2025
Incyte USD 4.28B 634.19M Sep/2025
Insmed USD 1.93B 149.77M Sep/2025
Ionis Pharmaceuticals USD 2.52B 58.16M Sep/2025
Neurocrine Biosciences USD 2.16B 409.5M Sep/2025
PTC Therapeutics USD 2.01B 265.07M Sep/2025
Sarepta Therapeutics USD 2.72B 65.32M Sep/2025
Ultragenyx Pharmaceutical USD 643.21M 76.58M Sep/2025
United Therapeutics USD 3.49B 332.9M Sep/2025